Display Settings:

Format

Send to:

Choose Destination

    AIDS. 2002 Aug 16;16(12):1686-9.

    M184V is associated with a low incidence of thymidine analogue mutations and low phenotypic resistance to zidovudine and stavudine.

    Ait-Khaled M, Stone C, Amphlett G, Clotet B, Staszewski S, Katlama C, Tisdale M; CNA3002 International Study Team.

    International Clinical Virology Unit, UK.

    The resistance of HIV clinical isolates with or without M184V was analysed in relation to plasma HIV-1-RNA level and time on therapy. The number of thymidine analogue mutations (TAMs) was lower in isolates with M184V, this was independent of plasma HIV-1-RNA level and time on therapy for T215F/Y, D67N and L210W. This suggests a direct effect of M184V on the reduced selection of TAMs. Lamivudine use was significantly associated with lower median fold resistance to zidovudine and stavudine.

    PMID: 12172093 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read Click here to read Click here to read

    Patient drug information

    • Lamivudine (Epivir®, Epivir-HBV®, Combivir® (as a combination product containing Lamivudine and Zidovudine), ...)

      Lamivudine (Epivir) is used in combination with other medications to treat human immunodeficiency virus (HIV) infection in patients with acquired immunodeficiency syndrome (AIDS). Lamivudine is not a cure and may not dec...

    • Lamivudine and Zidovudine (Combivir®)

      The combination of lamivudine and zidovudine is used to treat human immunodeficiency virus (HIV) in patients with or without acquired immunodeficiency syndrome (AIDS). Lamivudine and zidovudine are in a class of antivira...

    • Stavudine (Zerit®)

      Stavudine is used in combination with other antiviral medications to treat human immunodeficiency virus (HIV) infection in patients with or without acquired immunodeficiency syndrome (AIDS). Stavudine is in a class of an...